A review of matrix metalloproteinase-2-sensitive nanoparticles as a novel drug delivery for tumor therapy.
Int J Biol Macromol
; 262(Pt 2): 130043, 2024 Mar.
Article
em En
| MEDLINE
| ID: mdl-38340921
ABSTRACT
Matrix metalloproteinase-2 (MMP-2)-responsive nanodrug vehicles have garnered significant attention as antitumor drug delivery systems due to the extensive research on matrix metalloproteinases (MMPs) within the tumor extracellular matrix (ECM). These nanodrug vehicles exhibit stable circulation in the bloodstream and accumulate specifically in tumors through various mechanisms. Upon reaching tumor tissues, their structures are degraded in response to MMP-2 within the ECM, resulting in drug release. This controlled drug release significantly increases drug concentration within tumors, thereby enhancing its antitumor efficacy while minimizing side effects on normal organs. This review provides an overview of MMP-2 characteristics, enzyme-sensitive materials, and current research progress regarding their application as MMP-2-responsive nanodrug delivery system for anti-tumor drugs, as well as considering their future research prospects. In conclusion, MMP-2-sensitive drug delivery carriers have a broad application in all kinds of nanodrug delivery systems and are expected to become one of the main means for the clinical development and application of nanodrug delivery systems in the future.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Nanopartículas
/
Neoplasias
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article